Sever Pharma Solutions (SPS), a company that provides high potent drug development, has entered into a definitive agreement to acquire Foster Delivery Science (FDS), a contract research and manufacturing organization that specializes in hot melt extrusion of active pharmaceutical ingredients and polymers for highly regulated applications.
The deal, anticipated to be finalized later this month, is expected to expand SPS’s ability to leverage its knowledge in the aforementioned development of high-potent pharma products by incorporating its delivery system capabilities.
The newly acquired FDS plant will complement that of SPS’s existing operations in both Sweden and the Netherlands. SPS envisions that additional development of the FDS facility will result in a commercially licensed operation within the next few years.
“At Sever Pharma Solutions, we are very pleased to welcome FDS into our group and recognize the expertise in extrusion based implantable drug delivery that will complement our capabilities very well,” notes Kenneth Stokholm, CEO of Sever Pharma Solutions. “This will provide clients the opportunity to take advantage of end-to-end services in extrusion.”